



NDA 019527/S-031

SUPPLEMENT APPROVAL

Bausch Health US, LLC
Attention: Libette Luce, M.A.
Senior Director, Global Regulatory Affairs
400 Somerset Corporate Boulevard
Bridgewater, NJ, 08807

Dear Ms. Luce:

Please refer to your supplemental new drug application (sNDA), dated and received on June 14, 2019, and your amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for PEPCID (famotidine) for oral suspension.

This Prior Approval sNDA proposes to convert the Prescribing Information (PI) to Physician Labeling Rule (PLR) and Pregnancy and Lactation Labeling Rule (PLLR) formats.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in Structured Product Labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [FDA.gov](http://www.fda.gov)¹. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information [PI]), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the Guidance for Industry, *SPL Standard for Content of Labeling Technical Qs and As*². The SPL will be accessible from publicly available labeling repositories.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

Also, within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in Microsoft (MS) Word format that includes the changes approved in this supplemental application as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean MS Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Benjamin Vali, Regulatory Project Manager, at (301) 796-4261 or benjamin.vali@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology and Inborn Errors
Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure:

Content of Labeling
Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JOYCE A KORVICK
08/15/2019 10:42:58 AM